Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2010 Publisher: RenaCare NephroMed GmbH, Werrastr. 1 a, 35625 Hüttenberg, Germany Phone: +49 (0) 64 03 9 21 60 Fax: +49 (0) 64 03 9 21 63 E-mail: mail@renacare.com
Hyperphosphatemia associated with chronic renal insufficiency in patients undergoing dialysis.
Dosage should be effected individually. Unless a different dose has been prescribed, adults should take no more than 14 Renacet 475 mg film-coated tablets daily.
To achieve optimal efficacy, Renacet 475 mg should be taken during or immediately after meals
The usual dose is:
with breakfast: 1 to 2 film-coated tablets Renacet 475 mg,
with a snack: 1 to 2 film-coated tablets Renacet 475 mg,
with a main meal: 2 to 6 film-coated tablets Renacet 475 mg,
with supper: 2 to 4 film-coated tablets Renacet 475 mg.
Renacet 475 mg film-coated tablets should be taken with some liquid during or immediately after meals and must not be chewed.
Experience with children is not available.
Overdose would not be expected to cause gross hypercalcaemia except in patients taking excessive doses of vitamin D.
Measures in case of overdose: Discontinuation of the medicinal product and symptomatic treatment including lowering calcium levels e.g. administration of oral phosphates and non-saline laxatives such as lactulose.
3 years.
This medicinal product does not require any special storage conditions.
Pack sizes:
100 film-coated tablets
200 film-coated tablets
PVDC-coated PVC/aluminium foil blisters
No special requirements.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
